KHKetan Hatware

Ketan Hatware

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ketan Hatware has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current Developments in Palliative Care for Patients with Lung Cancer

    by Pravinkumar Ingle, Wei Kian Lian, Shui Jian Ting, Yew Ung Ngui, Chiau Win Chong, Hui Qing Teoh, Ketan Hatware

    Lung cancer has become one of the leading causes of death worldwide, following cardiovascular disease. It is defined as a disease in which lung cells divide uncontrollably, forming tumors that can either remain localised or spread to other parts of the body. Patients with lung cancer often experience symptoms, such as shortness of breath, pain, and loss of appetite, which can significantly impact their quality of life. Additionally, the treatment of lung cancer, particularly chemotherapy, can cause severe adverse effects. Risk factors, such as smoking, and alcohol consumption, can increase the likelihood of developing lung cancer. Therefore, it is essential to provide palliative care to all lung cancer patients to manage their symptoms and improve their quality of life. Simply relying on curative treatments, like chemotherapy and radiation therapy, may not be enough to achieve therapeutic goals. Effective communication between healthcare professionals and patients is crucial in ensuring that appropriate palliative care is provided. Misunderstandings can arise if there are gaps in communication between patients and healthcare professionals, leading to suboptimal care plans. Unfortunately, palliative care services are still not widely known or easily accessible. More research is needed to promote and expand access to palliative care services for patients with lung cancer. This review summarises the etiological factors, consequences, symptoms management, and the beneficial role of palliative care in surgery, chemotherapy, and radiotherapy for lung cancer patients. It also discusses implications for practice and research, as well as challenges in palliative and end-of-life care for these patients.

  • Open Access

    Development and Novel Therapeutics in Diabetic Retinopathy

    by Pravinkumar Ingle, Nurin Alesya Hamden, Wai Kei Soh, Rosalina Wibawa Hui Cen Loh, Ketan Hatware

    Diabetic retinopathy (DR) is a complication of diabetes mellitus which causes retinal damage which when left untreated will cause visual problems. As the prevalence of DR increases over the years, there is a need to optimise the currently available treatments as well as developing novel drugs to improve the therapy provided for the patients in the clinical practice. Several pharmacological therapies like, anti-vascular endothelial growth factor and anti-inflammatory therapies which include intravitreal, and implant of corticosteroids are significant in the management to decrease the risk of DR-related vision impairment. Clinical trials for novel drug therapies are still ongoing till this day to enhance the efficacy of DR treatment. Even though there are also modern treatments such as laser therapy for the patients, prevention should be done to lower the number of individuals affected by DR. Due to the complexity of DR, there are numerous obstacles to develop new medications for DR which include the increasing healthcare cost of DR treatment. New insights such as utilisation of artificial intelligence will be implemented into the management of DR as it has proved its potential in aiding the screening process. In parallel with the increase in DR prevalence and the number of treatments developed, extensive understanding of the mechanism of action of DR should be further improved to prevent more complications in the future. This review summarises the epidemiological trend, prevention strategies, challenges in treatment, current novel therapeutics (including drugs under clinical trials), future therapeutic trends and possibilities for implementing AI in the early diagnosis and management of DR.


  • Insights into the Diagnosis, Treatment, and Management of Prion Diseases

    by Vania Austine Callista, Ketan Vinayakrao Hatware, Pravinkumar Vishwanath Ingle

    The normal cellular prion protein (PrPC) can misfold into an infectious and pathogenic form (PrPSc) to produce prion diseases, also known as transmissible spongiform encephalopathies (TSEs), which are rare and deadly neurodegenerative conditions. The conversion of PrPC to PrPSc, which builds up as toxic aggregates in the central nervous system, is caused by sporadic, inherited, or acquired pathways. PrPSc-induced proteostasis failure, oxidative stress, neuronal toxicity, and progressive neurodegeneration are characteristics of pathogenesis. Due to their overlap with other neurodegenerative illnesses, prion diseases are still difficult to diagnose, even with breakthroughs in our knowledge of the molecular causes. Cerebrospinal fluid biomarkers, neuroimaging, EEG, and genetic testing are utilized in the diagnostic process. Methods like real-time quaking-induced conversion (RT-QuIC) provide high sensitivity. As there are currently no cures, the main goals of management are palliative care and symptom alleviation. Research is currently being conducted on experimental strategies that target PrP misfolding. These strategies include autophagy enhancers, monoclonal antibodies, antisense oligonucleotides, and small compounds. Artificial intelligence (AI) shows revolutionary promise by enhancing early diagnosis through biomarker analysis, neuroimaging interpretation, and EEG pattern identification. AI also improves clinical trial design, identifies tailored treatment approaches, and accelerates drug discovery. Furthermore, advancements in AI-based bioinformatics technologies have led to a better understanding of prion biology and strain diversity. The future holds promise for utilising cutting-edge treatment techniques, such as CRISPR and gene therapy, for targeted interventions, as well as combining AI with multimodal data to enhance diagnostic capabilities. There is optimism that the burden of prion disorders can be reduced, and the treatment of neurodegenerative illnesses can be improved through the integration of molecular research, novel treatments, and AI technology.


  • Open Access

    Novel Therapeutic Approaches in Alzheimer's Disease

    by Pravinkumar Ingle, Yen Ling Lee, Xin Yun Wong, Sok Pei Tan, Ee Jun Lim, Mei Yu Chin, Michelle Chieng Shu Zhen, Nurul Hasyanazifa Binti Safian, Ketan Hatware

    Alzheimer's disease (AD) is a neurological condition associated with a decrease in levels of acetylcholine and diminished cholinergic functions. This may be caused by the degeneration of cholinergic neurons in the brain, leading to cognitive deficits. Due to the difficulty and invasiveness of collecting cerebrospinal fluid (CSF) required for assessing conventional biomarkers, researchers are currently exploring less intrusive, less expensive, and more straightforward methods for diagnosing AD. Additionally, conventional interventions such as cholinesterase inhibitors like rivastigmine, donepezil, and galantamine are US FDA-approved drugs that are still effective for managing AD. The goal of this therapy is to increase acetylcholine levels in the brain by inhibiting the enzymes that degrade acetylcholine. Therefore, this therapeutic approach is useful for treating mild-to-moderate AD. However, only symptomatic treatment is currently available, and it can lead to serious adverse effects from conventional therapy. Thus, novel therapies for AD are needed in a growing global population. This manuscript provides information on various biomarkers with possible pathogenesis mechanisms, novel treatment strategies such as microalgae, HupA, cannabinoids, and the beneficial effects of coenzyme Q10, bacterial probiotics, omega-3 fatty acids, vitamin B12, and D3 in memory impairment for managing AD. Non-pharmacological treatments such as music therapy, Electroacupuncture (EA), or manual acupuncture (MA) also play an important role in enhancing the effectiveness of conventional pharmacological treatments for AD.


  • Open Access

    Evaluation of designed pharmaceutical pictograms among the Malaysian population

    by Anil Tumkur, Pravinkumar Ingle, Quinnie Ling Sze Ning, Nurul Asikin Bustamin, Tee Kai Heng, Chai Tze Leen, Ketan Hatware


  • Open Access

    d-α-tocopheryl polyethylene glycol 1000 succinate surface scaffold polysarcosine based polymeric nanoparticles of enzalutamide for the treatment of colorectal cancer: In vitro, in vivo characterizations

    by Disha Shah, Sankha Bhattacharya, Girdhari Lal Gupta, Ketan Vinayakrao Hatware, Arinjay Jain, Laxmi Manthalkar, Niraj Phatak, Putrevu Sreelaya


  • Targeted Delivery of Panitumumab-Scaffold Bosutinib-Encapsulated Polycaprolactone Nanoparticles for EGFR-Overexpressed Colorectal Cancer

    by Sankha Bhattacharya, Vipan Kumar Parihar, Neeraj Singh, Ketan Hatware, Amit Page, Mayank Sharma, Mahendra Kumar Prajapati, Abhishek Kanugo, Datta Pawde, Saurabh Maru, et al.

    Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib (BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & me... Graphical abstract


  • ANTIOXIDANT, SEDATIVE AND HYPNOTIC POTENTIAL OF MILK EXTRACT OF MYRISTICA FRAGRANS: A COMPLIMENTARY MEDICINE FOR THE MANAGEMENT OF INSOMNIA

    by Namita Raul, Ketan Vinayakrao Hatware, Sanjay Sharma, Kiran Patil, Sravani Karri, Rupesh Kumar Gautam

    The Myristica fragrans (MF) is well known in Ayurveda for many therapeutic uses. The present research work was carried out to investigate the antioxidant (in vitro), sedative and hypnotic effects of the MFmilk extracts in Wistar rats. The extraction was carried out by hot percolation and cold maceration methods. The phytochemical, HPLC and pharmacological evaluations were done. The overall sedative and hypnotic effects of the different extracts were evaluated using the parameters locomotor activity, muscle strength and thiopental induced sleeping time. The milk extracts shown the presence of quercetin. It was confirmed using HPLC analysis, which might be responsible for its in-vitro antioxidant activity. The extract also showed the significant (P<0.05) sedative and hypnotic effect at 50 mg/kg, 100 mg/kg and 200 mg/kg on oral administration. Consequently, the treated groups have shown a significant increase in thiopental induced sleeping time. The study concluded that the milk extracts possess antioxidant, sedative and hypnotic activity. further research is needed to develop suitable formulation and to establish the mechanism of action of milk extract of MF.

  • PREVENTION OF APPARENT ADIPOSITY BY FRACTIONS OF DISTILLED COW URINE: A NON-INVASIVE APPROACH

    by Ketan Hatware, Sanjay Sharma, Ashwini Deshpande, Kiran Patil, Sravani Karri, Rupesh Gautam

    Owing to the multifactorial pathological conditions management of obesity is a challenging problem. finding an effective and safe remedy is a huge area of interest for many scientists and healthcare professionals in the field of biomedicine. There is a traditional claim that fresh cow urine and its distillate have anti-obesity activity. The present study aimed to assess the bioactive fraction of distillated cow urine having anti-obesity potential. Distilled cow urine was extracted by liquid-liquid extraction method using different solvents. Distilled cow urine and all the fractions were assessed for the anti-obesity activity by analysing non-invasive parameters. The distilled cow urine and it’s methanolic as well as butanolic fractions show significant anti-obesity potential. It has been found that body weight reduced without affecting food consumption. This effect was probably due to the reduction in dietary fat absorption by reducing the pancreatic lipase activity and enhancing its excretion in faeces. Further research is required to explore the exact mechanism of action.